FDA PMA FDA Class 3 Approved 🇺🇸 United States

Test, Hepatitis B (B Core, Be Antigen, Be Antibody, B Core Igm)

PMA: P190005 · Decision Feb 3, 2021
Classifications
1
FEI Numbers
27
Registration Numbers
27

Basic Information

Device Name
Test, Hepatitis B (B Core, Be Antigen, Be Antibody, B Core Igm)
Trade Name
Elecsys Anti-HBe, PreciControl Anti-HBe
PMA Number
P190005
Device Class
FDA Class 3
Product Code
LOM
Generic Name
Test, hepatitis b (b core, be antigen, be antibody, b core igm)
Medical Specialty
Unknown
Advisory Committee
Microbiology
Decision
Approved
Decision Code
APPR
Decision Date
February 3, 2021
Date Received
March 1, 2019
Expedited Review
N
Docket Number
21M-0178

Advisory Committee Statement

Approval for the Elecsys Anti-HBe The device is an immunoassay for the in vitro qualitative detection of total antibodies to hepatitis B e antigen (anti-HBe) in human adult serum or plasma (potassium EDTA, lithium heparin, sodium citrate, sodium heparin) from individuals with symptoms of hepatitis or at risk for hepatitis B virus (HBV) infection. Assay results, in conjunction with other laboratory results and clinical information may be used as an aid in the diagnosis of hepatitis B virus (HBV) infection in patients with symptoms of hepatitis or who may be at risk for HBV infection. A reactive test is presumptive laboratory evidence of HBV seroconversion. Further HBV serological marker testing is required to define the specific disease state. The PreciControl Anti-HBe is used for quality control of the Elecsys Anti-HBe immunoassay on the cobas e 602 immunoassay analyzer. The performance of PreciControl Anti-HBe has not been established with any other anti-HBe assay.

Classifications

This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.

Product Code Device Name
LOM Test, Hepatitis B (B Core, Be Antigen, Be Antibody, B Core Igm)